Nuformix plc (LON:NFX – Get Free Report)’s stock price fell 12.5% during trading on Wednesday . The stock traded as low as GBX 0.05 ($0.00) and last traded at GBX 0.06 ($0.00). 19,272,414 shares traded hands during mid-day trading, an increase of 383% from the average session volume of 3,989,162 shares. The stock had previously closed at GBX 0.06 ($0.00).
Nuformix Trading Up 1.6 %
The company has a debt-to-equity ratio of 1.17, a current ratio of 1.12 and a quick ratio of 3.35. The stock has a market cap of £507,972.20, a P/E ratio of -1.63 and a beta of 1.22. The firm’s fifty day moving average price is GBX 0.16 and its two-hundred day moving average price is GBX 0.18.
About Nuformix
Nuformix plc operates in the field of pharmaceutical development for treating fibrosis and oncology through drug repurposing in the United Kingdom. It offers NXP001, which has completed Phase 1 for use in oncology supportive care. The company is also developing NXP004, a novel form of Olaparib, which is in the IP generation phase for treating oncology; and NXP002 that is in pre-clinical stage for the treatment of idiopathic pulmonary fibrosis.
Read More
- Five stocks we like better than Nuformix
- The Significance of a Trillion-Dollar Market Cap Goes Beyond a Number
- Rocket Lab Stock Soars: Should Investors Chase the Rally?
- 3 Stocks to Protect Your Portfolio from the Coronavirus Contagion
- KB Home Slips After Earnings: What’s Next for Homebuilders?
- What is the FTSE 100 index?
- Micron Stock Soars as AI Demand Fuels Big Q4 Earnings Beat
Receive News & Ratings for Nuformix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nuformix and related companies with MarketBeat.com's FREE daily email newsletter.